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Large population-based cohort studies, through their prospective collection of
a broad range of health information, represent an invaluable resource for novel
insights into the pathogenesis of human diseases. Collection and cryopreserva-
tion of viable cells from blood samples is becoming increasingly common in
large cohorts as these cells are a valuable resource for immunophenotyping and
functional studies. The cryopreservation of peripheral blood mononuclear cells
(PBMCs), thawing, and immunophenotyping protocols used to immunopheno-
type 9938 participants in the Health and Retirement Study (HRS) are described.
The extensive quality control involved in a large-scale immunophenotyping
epidemiological study is also outlined. The existing literature on the effect of
cryopreservation on various immune cell subsets including T, B, NK cells,
monocytes, and dendritic cells is provided. C© 2018 by John Wiley & Sons, Inc.
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INTRODUCTION
Large population–based cohort studies prospectively collect a broad range of health
information along with social, behavioral, and psychological information on several
thousand participants over extended time periods. They represent an invaluable re-
source for novel insights into the pathogenesis of human diseases and it is esti-
mated that 1.5 million volunteers in the U.S.A. have participated in various cohorts
funded by the National Institutes of Health (https://www.genome.gov/pages/about/od/
reportspublications/potentialuscohort.pdf). The majority of these studies have success-
fully collected and stored a variety of biospecimens using standardized protocols to enable
measurement of biomarkers to further the understanding of disease etiology, early de-
tection, or prognosis of various diseases. Since appropriate cryopreservation techniques
to process and store viable cells are both costly and labor intensive, viable peripheral
blood mononuclear cells (PBMCs) are not commonly stored in large population studies.
However, PBMCs can be used to study differences in cellular distribution and perform
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functional assays that help understand biological consequences of genetic variants as-
sociated with disease outcomes in large-scale genomics studies, several population
studies such as the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screen-
ing Trial (Landgren et al., 2009), Cancer Prevention Study-3 (CPS-3) (Stevens et al.,
2007), Coronary Artery Risk Development in Young Adults (CARDIA) (Friedman et al.,
1988; Hughes et al., 1987), large biobanks such as the UK Biobank (500,000 partici-
pants) (Elliott, Peakman, & UK Biobank, 2008), and the All Of Us Research Program
(https://allofus.nih.gov/) (1,000,000 participants) have cryopreserved cells for use in
future immunophenotyping and functional studies. These studies have used a variety
of methods to cryopreserve PBMCs. A majority of studies including PLCO, CPS-3,
UK Biobank, and the All Of Us Research program are cryopreserving whole blood
with dimethyl sulfoxide (DMSO), while studies such as CARDIA have opted to isolate
PBMCs prior to cryopreservation. Several studies have reported that differences in cry-
opreservation protocols, time intervals between sample collection and processing, and
procedures for thawing samples all influence the distribution of cells after cryopreserva-
tion (Kutscher et al., 2013; Lemieux, Jobin, Simard, & Néron, 2017).
Recently, blood samples were collected and processed to obtain cryopreserved PBMCs in
the Health and Retirement Study (HRS), a nationally representative longitudinal survey
of >37,000 individuals over the age of 50 in 23,000 households in all 48 contiguous states
in the U.S.A. A multiparameter flow cytometry on cryopreserved PBMCs was performed
to estimate 33 immune cell subsets, including T cells, B cells, natural killer (NK) cells,
dendritic cells (DC), and monocytes along with 3 B cell subsets, 19 T cell subsets, 2 NK
subsets, 2 DC subsets, and 2 monocyte subsets using two flow cytometers, an LSRII
and a FORTESSA X20 (BD Biosciences). Venous blood samples were collected from
9938 HRS participants in 7300 households during 2016 and 2017. Blood samples were
collected directly into a CPTTM vacutainer tube (BD Biosciences) at participant homes
in all 48 contiguous states in the U.S.A. and shipped daily at room temperature to the
Advanced Research and Diagnostics Laboratory (ARDL) at the University of Minnesota.
More than 95% of the samples were processed within 48 hr of sample collection. PBMCs
were isolated from venous using the CPTTM vacutainer and subsequently cryopreserved
and stored for future studies. T cryopreservation, thawing, and immunophenotyping
protocols used in the HRS are described.
BASIC
PROTOCOL 1
CRYOPRESERVATION OF PBMCs USING CPTTM VACUTAINER AS
COLLECTION TUBE
Isolation of PBMCs from whole blood was performed prior to cryopreservation using
CPTTM vacutainer tubes containing a citrate anticoagulant that lies above a polyester
barrier in the tube and a Ficoll-Hypaque density gradient lies below it. This tube allows
for both sterile blood collection and density-based cell separation in a single container.
Centrifugation of the CPTTM tube yielded a layer of PBMCs that was transferred under
sterile conditions in preparation for cryopreservation. The final cell suspension was
dispensed into aliquots in cryovials that were placed at –80°C using controlled rate
freezing to gradually lower the temperature of the suspension to –80°C in preparation
for final storage conditions in liquid nitrogen vapors at –140°C to –180°C.
NOTE: Work in a biological safety cabinet. Use sterile technique throughout.
Materials
HBSS-PS (see recipe)
Hemolytic buffer (see recipe)
20% FCS (see recipe)
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20% DMSO (see recipe)
Liquid nitrogen
Vacutainer CPTTM (cell preparation tube with sodium citrate, Becton Dickinson,
cat. no. 362761)
Benchtop centrifuge
5-, 10-, and 25-ml disposable sterile pipets
50-ml conical tubes, sterile
Hemacytometer (Bright Line, Improved Neubauer, 0.1-mm deep)
American Optical Zeiss microscope, bi-pin (low pressure), 10× ocular
Shallow trays
Cryovial holder
2-ml sterile cryovials, sterile, screw cap
Cardboard box
Freezing container (Mr. Frosty, Nalgene)
Isolate PBMCs
1. Keep CPTTM tubes at room temperature and in an upright position until they are
ready to process for 30 min after unpacking.
During shipment, it is not always possible to control the tube temperature (i.e., high
ambient temperature in summer or low ambient temperature in winter). It is crucial for
the proper functionality of the CPT Ficoll layer that the processing be done at room
temperature between 20°C and 25°C. Incubating tubes 30 min at room temperature
allows the tube temperature to equilibrate prior to processing.
2. Mix CPTTM tubes by inverting gently eight to ten times prior to centrifugation.
Centrifuge 30 min at 1700 × g, room temperature.
Centrifugation time is increased to 30 min compared to the 20 min recommended by the
manufacturer to reduce contamination of the PBMC preparation by red blood cells.
3. Following centrifugation, ensure that proper separation of tube components by
density gradient has occurred. From top to bottom, separation should show a plasma
layer, PBMC layer, gel layer, Ficoll layer, and then red blood cells (Fig. 1).
4. Using a sterile 10-ml pipet, aspirate plasma on the gel by tilting the tube and having
the pipet tip touch the side of the tube, not the gel barrier. Transfer all of plasma
from the CPTTM tube into one labeled 50-ml conical tube.
5. Using a new, sterile 5-ml pipet, add 3 ml HBSS-PS to each CPTTM tube by dispensing
it down the side of the CPTTM tube to rinse tube, followed by gently pipetting up
and down two times to ensure capture of all cells. Using the same pipet, avoiding
pipetting gel with the liquid, transfer all HBSS-PS/sample mixture to the 50-ml
conical tube containing original plasma.
6. Using a new, sterile 25-ml pipet, add additional HBSS-PS to bring volume in the
conical tube to 35 ml.
7. Centrifuge conical tubes 10 min at 330 × g, room temperature. After centrifugation,
visually check for an intact pellet. Pour off supernatant and disperse cell pellet by
gently tapping tube or gently “racking” (racking involves drawing each conical tube
at a 45° angle across the top of a plastic tube rack).
Do not vortex samples to minimize damage to cells.
8. Using a sterile 5-ml pipet, add 3 ml hemolytic buffer and gently mix. Incubate 5 min
at room temperature, then add 3 ml HBSS-PS using a new 5-ml sterile pipet and
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Figure 1 Separation of blood component using a CPTTM vacutainer. The diagram shows the
separation of the blood component after centrifugation of the CPTTM tube. The plasma (white) lies
on top of the PBMCs layer (light grey). Below the PBMC is the polyester gel (black). At the bottom
of the tube, the red blood cells (RBC, dark grey) within the density gradient layer can be found.
When CPTTM tubes are used within the recommended time guidelines from the manufac-
turer, there is very little red blood cells contaminant within the PBMC layer; however,
due to the time delay of 24 to 48 hr, contamination of the PBMC layer by RBC is more
likely, therefore, an RBC lysis step was included.
9. Centrifuge 10 min at 330 × g, room temperature. Visually check for an intact pellet
to ensure that proper centrifugation has occurred. Pour off supernatant and disperse
cell pellet by gently tapping tube or gently “racking” (see step 7; do not vortex).
10. Add 10 ml HBSS-PS to cell pellet.
Cryopreserve PBMCs
11. Pipet 10 µl of resuspended PBMCs from step 11 onto a hemacytometer.
12. Count cells located in the four outer squares of the hemacytometer using an optical
microscope and calculate cell count using the following equation:
total cell number = cell count × 16 × resuspension volume × 2500
13. Calculate the total volume of 20% DMSO needed for a final cell concentration of
4 × 106 cells/ml using the following equation. Use this volume to resuspend the
PBMCs in steps 16 and 18.
volume of medium (ml) = total cell number/(4 × 106)
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15. Pour off supernatant. Gently disperse cell pellet. Add appropriate amount (half
of the volume calculated in step 14) of 20% FCS in supplemented RPMI with
HEPES.
16. For the freezing procedure, prepare a melting ice bath in a shallow tray. Place
cryovial holder containing a labeled 2-ml cryovial into ice bath. Prepare a second
ice bath. Place the 50-ml conical tube containing lymphocyte suspension into the
second ice bath. Pipet the estimated amount of 20% DMSO in RPMI supplemented
with HEPES (half of the volume calculated in step 14) into a labeled 50-ml conical
tube and place this into the ice bath with the specimen.
17. Dilute cell suspension with an equal volume of cold 20% DMSO (1:1 ratio of
RPMI to DMSO). Using a sterile pipet, very slowly add the appropriate volume
(calculated in step 14) dropwise with continuous mixing of the suspension tube to
avoid concentration gradients of DMSO.
18. Using the same pipet, transfer 1 ml of suspension into the appropriate pre-chilled,
labeled 2-ml cryovial. Screw caps tightly. Keep cryovials on ice water until ready to
freeze. Do not allow cells to sit in DMSO for >30 min prior to freezing.
19. Transfer vials into a cardboard box, keeping in upright position. Place box in a
styrofoam container (controlled-rate freezer or a Mr. frosty container may be used
if available). Place box at –80°C and transfer cryovials to liquid nitrogen after a
minimum of 8 hr or maximum of 24 hr at –80°C for long-term storage.
Typically, two to three cryovials (each containing 4 to 6 million PBMCs) are obtained
from a single CPTTM processed using the conditions described in this protocol.
BASIC
PROTOCOL 2
THAWING CRYOPRESERVED PBMCs FOR IMMUNOPHENOTYPING
The protocol below describes how cryopreserved PBMCs were thawed and rested in
preparation for immunophenotyping.
Materials
Cryopreserved PBMC vial (see Basic Protocol 1)
Complete RPMI (see recipe), prewarmed
100 U/µl DNase (Life Technology, cat. no. 18047019), store until manufacturer
expiration date at –20°C
1× PBS (see recipe)
37°C water bath
Transfer pipets
15-ml conical polypropylene tubes
Centrifuge
37°C, 5% CO2 water-jacketed incubator (95% humidity)
1. Place a cryopreserved PBMC vial into a 37°C water bath. Submerge cryovial halfway
in bath and thaw for 60 sec.
PBMCs were frozen at 4 million cells in 1 ml freezing medium. The authors found that
60 sec was the optimal time to thaw frozen PBMCs. Larger volumes may require a longer
duration in the bath. The thawing step can be done in batches of ten samples. Thawing
larger batches of cryovials increases failure rate during immunophenotyping.
2. Slowly add 1 ml of warmed (37°C) complete RPMI dropwise to thawed PBMCs
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3. Pour thawed PBMCs in 5 ml complete RPMI into a 15-ml conical tube that has been
warmed to 37°C (no pipetting). Wipe down the tube so that no water from the water
bath is transferred along with cells.
Excessive pipetting during the thawing process is disruptive to some immune cell subsets.
At this step, pipetting can be avoided by pouring the cells rather than pipetting them.
4. Rinse cryovials one time with 2 ml of warm complete RPMI, pour PBMCs into the
conical tube containing cell mixture (no pipetting).
5. Incubate PBMCs 5 min in 37°C water bath.
Since multiple samples are being thawed at once for the study, this allows all the samples
to rest shortly prior to the spin to remove DMSO.
6. Centrifuge PBMCs 10 min at 330 × g, room temperature.
7. Pour off supernatant (this will leave a small amount of complete RPMI behind that
aids in pellet resuspension in step 8).
8. Add 1 ml of prewarmed complete RPMI with 50 U/ml DNase. Mix by flicking or
racking the tube (avoid pipetting up and down).
9. Incubate PBMCs for 1 hr in a 37°C, 5% CO2 water-jacketed incubator (95% humid-
ity). Leave cap of the conical tube slightly loose so that gas transfer can occur.
There is no clear consensus on the amount of time the cells should be rested after thaw-
ing and prior to immunophenotyping. Resting PBMCs 1 hr at 37°C was necessary to
provide immunophenotyping results in cryopreserved PBMCs comparable to whole-blood




QUALITY CONTROL AND IMMUNOPHENOTYPING OF PBMCs
Since two flow cytometers are used and immunophenotyping is performed over 18
months, several quality control steps that monitor flow cytometer, antibodies, and repro-
ducibility across technicians are described. The steps of the staining protocol are also
described.
Materials
CS&T research beads (setup beads, BD Biosciences, cat. no. 655050), store until
manufacturer’s expiration date at 4°C, away from light
1× PBS (see recipe)
Ultra Rainbow Beads (URBs, Spherotech, cat. no. URFP-30-2), store until
manufacturer’s expiration date at 4°C, away from light
Antibody cocktail (see Tables 1 and 2)
Viability dye (see recipe)
LSRII (BD Biosciences) with a 488-nm blue laser (4 colors), 633-nm red laser (2
colors), 407-nm violet laser (4 colors), and 355-nm UV laser (3 colors)
FORTESSA X-20 (BD Biosciences) with a 488-nm blue laser (4 colors), 633-nm
red laser (2 colors), 407-nm violet laser (4 colors), 355-nm UV laser (3 colors),
and 561-nm yellow laser (2 colors)
FACSDiva software
Centrifuge
15-ml conical polypropylene tube
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Prepare flow cytometer (quality control)
1. Turn on flow cytometer and lasers if necessary.
2. Refill sheath tank, empty waste tank, and prime two times.
3. Set flow speed to low and fine adjust knob to the middle position (five turns). Run
water for 5 min.
4. After 20 min of warm up, add one drop of CS&T setup beads to 350 µl of 1× PBS
in a 5-mL round-bottom polystyrene tube.
5. Open cytometer setup page in FACSDiva and run beads. Ensure that appropriate lot
number is used and follow prompts from software.
6. If the CS&T beads pass, start next quality control step. If the CS&T beads do not
pass, call for service.
If the CS&T reports are monitored closely, it is possible to detect changes in laser
alignments before CS&T fails and call for service. Slight increases either in bright beads
CVs or in ΔPMTVs or changes in laser delay are indicative of potential shifts in laser
alignments. It is preferred to catch this drift early so a service visit can be scheduled at
a convenient time rather than as an emergency service call.
7. Add one drop of URBs to 350 µl of 1× PBS.
8. Set up voltages for each detector so that the beads fall within a gate of choice for each
detector. Use these voltages as a base to save the application settings in FACSDiva,
which will allow the software to adjust the voltages for each detector for minimal
changes in PMTV.
9. Use the application settings for each subsequent URB that will be run on the flow
cytometer. Establish a range for the median fluorescence intensity (MFI) for each
detector (this range will be used to check subsequent URB).
10. Run the URB on low with the fine adjust knob set at the middle (five turns).
11. Record 30,000 events.
12. For the URB to pass quality control, the MFI for all detectors of the blue and red
lasers must be within 3% of the average calculated at the beginning of the study,
and within 5% of the average for each detectors for the violet and UV lasers (Kalina
et al., 2012).
13. Thaw a compensation PBMC vial, which will be processed as a sample (see below).
Vials of cryopreserved PBMCs were set aside from a healthy volunteer to be used daily
as a compensation sample. Daily compensation does improve data quality and will avoid
adjustment of compensation post data acquisition.
14. After the 1-hr rest, resuspend the compensation sample in 2 ml of 1× PBS.
15. Add 100 µl of cells to 20 pre-labeled 5-ml round-bottom 12 × 75–mm polystyrene
tubes one per each individual antibody listed in Tables 1 and 2 and an unstained
sample.
Information about antibodies and viability dyes (i.e., manufacturer and product number)
is listed in Tables 1 and 2. Store until manufacturer’s expiration date at 4°C, away from
light.
In addition to the standard quality control procedures to ensure reliability of flow cy-
tometers, draw ten CPTTM tubes from four healthy volunteers before the start of the
study. PBMCs were isolated and aliquots were frozen at a concentration of 2 million
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Table 1 Antibody List and Volumes Per Sample for Panel 1 that Characterize T and B Cells





NA NA BD (659611) 55
Viability dye NA FVS 570 (PE) BD (564995) 12
CD3 UCHT1 APC BD (555335) 4.4
HLA-DR G46-6 PE-CF594 BD (562331) 1.1
CD19 SJ25C1 PE-Cy7 BD (557835) 1.1
CD27 O323 FITC Biolegend (302806) 2.75
CD8 RPA-T8 BUV395 BD (563796) 1.1
IgD IA6-2 BUV737 BD (564687) 1.1
CCR7 G043H7 BV421 Biolegend (353208) 2.75
CD28 CD28.2 BV510 Biolegend (302936) 2.75
CD95 DX2 BV605 Biolegend (305628) 2.75
CD45RA HI100 BV711 Biolegend (304138) 2.75
CD4 RPA-T4 APC-Cy7 BD (557871) 1.1
aBD, BD Biosciences.







Brilliant stain buffer NA NA BD (659611) 55
Viability dye NA FVS 570 (PE) BD (564995) 12
CD3 UCHT1 APC BD (555335) 4.4
HLA-DR G46-6 PE-CF594 BD (562331) 1.1
CD19 SJ25C1 PE-Cy7 BD (557835) 1.1
CD11c B-ly6 BB515 BD (564490) 1.1
CD20 2H7 BUV395 BD (563781) 1.1
CD16 3G8 BUV737 BD (564433) 1.1
CD56 NCAM16.2 BV421 BD (562751) 1.1
CD14 MOP9 BV510 BD (563079) 1.1
CD123 9F5 BV711 BD (563161) 1.1
CD45 2D1 APC-Cy7 BD (560178) 0.55
aBD, BD Biosciences.
(mean ±2 standard deviations) was established before starting the study with four
technicians processing and analyzing each of the four controls three times each (12
replicates/control). These controls were subsequently used to monitor antibody stocks,
individual technique, and to train new flow technicians.
Prior to running study samples, new team members should process and analyze each
control at least three times and be certified to analyze study samples only after all
values are within the pre-established range. As experimental reproducibility controls,
each experimenter should process one control per week along the HRS samples and
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ensure that all cell subsets are within the established ranges. If two cell populations
in a particular control are outside established ranges, analyze study samples on that
day, and have the same technician repeat the control on the following day. If the cell
populations continue to be out of range, then no study samples are analyzed and data
from study samples analyzed the previous day are discarded. If three populations are out
of range, analyze study samples only after controls are repeated and pass established
quality control parameters on the following day. If controls do not pass on 2 consecutive
days, the flow cytometer should be serviced prior to study samples being analyzed.
Stain for immunophenotyping
16. Prepare antibody cocktail for panels 1 and 2 as described in Tables 1 and 2, respec-
tively.
The antibody cocktail (antibody clone choices and fluorochrome choices) was optimized
using a combination of the classic fluorescence minus one (FMO) experiments and a
series of titration experiments. The cocktail can be prepared once a day and stored at
4°C in the dark. If this cocktail is going to be stored for longer than 4 hr, further validation
is required.
a. Prepare a pre-mix with antibodies and brilliant stain buffer (required
when two or more brilliant fluorochrome conjugated antibodies are used)
for samples, prepare 10% overage (see Tables 1 and 2 for specific
volumes).
b. Add viability dye to tubes of cells after the panel mix is added.
It is used slightly below the manufacturer’s recommended amount.
17. At the end of the 1-hr PBMC rest (see Basic Protocol 2, step 9), add 10 ml of 1×
PBS (room temperature) to wash cells prior to staining.
18. Centrifuge cells 10 min at 330 × g, room temperature.
19. Pour off supernatant and pipet the remaining supernatant completely.
20. Resuspend cells in an appropriate volume of 1× PBS to achieve a final volume of
200 µl. Mix by flicking the tube.
Depending on the level of experience of the technician, the volume of 1× PBS added can
vary slightly. The point is to minimize the volume of wasted cells and be as close to the
final volume of 200 µl. The volume of 1× PBS required is generally between 160 and
180 µl.
21. Add 100 µl of cells to two pre-labeled 5-ml round-bottom polystyrene tubes (panel
1 and panel 2).
22. Add 71.5 µl of panel 1 premix or 62.5 µl of panel 2 premix to the appropriate tubes.
Mix tube gently by agitating the tube rack.
It is crucial to ensure that all liquid (cells and antibody panel mix) is at the bottom of the
tube. Any cells potentially stuck to the side of the tube will remain unlabeled and will be
erroneously counted in the negatively stained fraction.
23. Add 12 µl of viability dye to each tube.
24. Incubate exactly 20 min at room temperature protected from light.
25. Add 800 µl of 1× PBS.
26. Centrifuge cells 10 min at 330 × g, room temperature.
27. Pipet off supernatant. Resuspend stained PBMCs in 500 µl of 1× PBS and store on
ice in the dark until flow cytometry. Run samples within 4 hr of staining. Phenotypic
Analysis
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REAGENTS AND SOLUTIONS
Complete RPMI
To prepare 500 ml:
445 ml 1× RPMI (Gibco, cat. no. 11875093)
50 ml fetal bovine serum (10%) (FBS, Invitrogen, cat. no. 10437-028)
5 ml penicillin/streptomycin (100 U/ml) (PS, Gibco, cat. no. 15140-122)
Store 7 days at 4°C
DMSO, 20%
To the top of a 250-ml filter flask, add 200 ml of 20% FCS (see recipe). While slowly
swirling a pipet in the FCS, add 50 ml dimethyl sulfoxide (DMSO, Sigma, cat. no.
D5879) to the FCS by using a disposable pipet (DMSO must be added slowly or
protein will precipitate and the filter will clog). Store 7 days at 4°C.
FCS, 20%
To the top of a 500-ml sterile filter flask, add 400 ml supplemented RPMI with
HEPES, and then add 100 ml fetal calf serum (FCS) (also called fetal bovine serum,
FBS, Invitrogen, cat. no. 10437-028). Filter and store 7 days at 4°C.
HBSS-PS
5 ml penicillin/streptomycin (PS: 10,000 U/ml penicillin/10,000 µg/ml
streptomycin, Gibco, cat. no.15140-122)
495 ml 1× calcium and magnesium–free Hank’s balanced salt solution (HBSS,
Gibco, cat. no. 14170-112)
Store 30 days at 4°C
Hemolytic buffer
8.3 g NH4Cl (500-g bottle, dry powder)
1.0 g NaHCO3 (500-g bottle, dry powder)
0.04 g disodium EDTA (Fisher, cat. no. S311-100)
Dilute to 1000 ml with sterile water
Sterilize by filtration in 0.45-μm filter flask
Store 6 months at 4°C
PBS, 1×
Add 2 liters of 10× phosphate buffered saline, pH 7.4 (PBS, Lonza, cat. no. 17515Q)
to 18 liters of deionized water. Store until manufacturer’s expiration date at room
temperature.
Supplemented RPMI (HEPES) buffer
5 ml heparin sodium injection, USP (Sagent, cat. no. NDC 25021-400-10)
5 ml penicillin/streptomycin (PS: 10,000 U/ml penicillin/10,000 µg/ml
streptomycin, Gibco, cat. no. 15140-122)
5 ml thawed 100× L-glutamine (mix well prior to addition; Gibco, cat. no.
25030-081)
480 ml 1× RPMI medium 1640 (RPMI with HEPES, Gibco, cat. no. 22400-89)
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Viability dye
594 µl 1× PBS (see recipe)
6 µl viability dye stock (Viability Dye-FVS 450, BD Biosciences, cat. no. 564995),
prepared according to manufacturer’s recommendations
Store 90 days at –20°C
COMMENTARY
Background Information
Numerous publications have reported on
the effect of cryopreservation on various im-
mune subsets (Draxler, Madondo, Hanafi, Ple-
banski, & Medcalf, 2017; Lemieux et al.,
2017; Verschoor, Kohli, & Balion, 2017). The
two major types of cryopreservation evalu-
ated across studies are cryopreserved whole
blood and PBMCs isolated via a density gra-
dient and then cryopreserved. Several stud-
ies compared the viability and functionality
of cryopreserved whole blood and cryopre-
served PBMCs. DNA repair capacity and mu-
tagen sensitivity assays showed similar results
in cryopreserved whole blood and cryopre-
served PBMCs (Cheng, Wang, Spitz, & Wei,
2001). While it is possible to stain immune
cells for surface markers for immunopheno-
typing, fix, and then freeze at a lower tem-
perature (–20°C or –80°C), this method does
not result in viable cells for future functional
assays (Pinto et al., 2016; Madelaine Paredes,
Tadaki, Sooter, Gamboni, & Sheppard, 2017).
Studies have also evaluated different methods
for thawing samples with some studies thaw-
ing samples and performing immunopheno-
typing without any rest period, while other
studies had rest periods (incubating cells at
37°C) of 1 to 24 hr prior to immunophenotyp-
ing (Lemieux et al., 2017; Wang et al., 2016,
Kutscher et al., 2013). In general, these studies
have shown that a short rest period of 1 hr gen-
erally improves comparability of various im-
mune subsets in cryopreserved cells and fresh
cells (Lemieux et al., 2017), although a longer
rest period of up to 24 hr results in higher pro-
portion of activated cells in the cryopreserved
sample (Sattui et al., 2012). An 18-hr rest pe-
riod reduced the number of apoptotic cells in
thawed PBMCs and positively affected lym-
phocyte functionality (Wang et al., 2016). Pub-
lished effects of cryopreservation and thawing
procedures on the enumeration and functions
of individual immune subsets are reviewed
below.
T cells
Since T cells and their subsets are useful
in a number of applications such as monitor-
ing HIV patients (Sattui et al., 2012; Zhang,
Nilles, Johnson, & Margolick, 2016), func-
tional studies (Cheng et al., 2001), activation
studies (Lemieux et al., 2017), and vaccine
testing (Kutscher et al., 2013; Wang et al.,
2016), the effect of cryopreservation on T
cells has been extensively investigated. Nu-
merous studies showed no effect of cryopreser-
vation in the enumeration of T cells, helper
and cytotoxic T cells (Draxler et al., 2017;
Weinberg et al., 2010; Verschoor et al., 2017;
Sattui et al., 2012). Though cryopreservation
did not affect the distribution of helper and
cytotoxic T cells, some T cell subsets such as
‘naive helper,’ ‘central memory helper,’ and
‘cytotoxic’ were significantly lower and cy-
totoxic effector T cells were higher in cry-
opreserved samples compared to fresh whole
blood (Costantini et al., 2003). A significant
decrease in T cells and helper T cells observed
after cryopreservation was not rescued by a
1-hr rest (Lemieux et al., 2017). Although
there were significant differences in several
T cell subsets when immunophenotyping was
performed on cryopreserved PBMCs without
resting the cells, the proportion of naı̈ve, cen-
tral memory, effector, effector memory, Th1,
and Th2 as well as activated subsets within
the helper and cytotoxic T cell populations did
not show any significant change with cryop-
reservation after a rest period (Lemieux et al.,
2017). In Lemieux’s study, a 1-hr rest period
also showed greater concordance of helper and
cytotoxic T cell subsets with the fresh sample
than with the sample that was rested for 24 hr
or not rested at all (Lemieux et al., 2017). In
contrast, a rest period of 18 hr after thawing
improved lymphocyte functionality. Smaller T
cell subsets such as regulatory helper T cells
(Tregs) and naı̈ve helper or naı̈ve cytotoxic
T cells measured levels are comparable be-
tween cryopreserved PBMCs and fresh blood
(Wang et al., 2016). Tregs play a major role in
immune homeostasis and down-regulate both
Th1 and Th2 responses (Zhang, Zhang, Gu,
He, & Sun, 2014) and are sensitive to cryop-
reservation. Though helper T cell enumeration
remained constant between fresh and frozen
PBMCs, Treg counts were reduced in cry-
opreserved PBMCs regardless of HIV status
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PBMCs were not rested after being thawed.
Lemieux (2017) showed that a rest of 1 hr
was sufficient to restore T cell phenotype in
thawed PBMCs, making it comparable to fresh
samples. They also showed that using a more
sensitive flow data analysis method (viSNE)
compared the more conventional flow anal-
ysis method (FlowJo or FCS express) could
improve detection of poorly represented pop-
ulations such as Tregs (Lemieux et al., 2017).
Resting thawed PBMCs for 4 hr has also been
shown to restore CD120b expression on Tregs
regardless of HIV status (Zhang et al., 2016),
although a number of Tregs did not seem to be
affected by either cryopreservation or duration
of the rest period after thawing. Other studies
showed that Tregs were decreased, but highly
correlated, in cryopreserved samples (Elkord,
2009) without any resting of thawed samples.
B cells
B cells can be successfully isolated and im-
mortalized in thawed whole blood that was
cryopreserved even after a delay of 24 hr after
blood collection (Peakman and Elliot, 2008).
B cells are increased in cryopreserved blood
compared to a fresh sample (Verschoor et al.,
2017). The increase in B cells in cryopreserved
PBMCs observed by Lemieux et al. remained
unchanged by either a 1- or 24-hr rest period
(Lemieux et al., 2017).
NK cells
NK cell frequencies are lower in cryopre-
served PBMCs but still highly correlated in
cryopreserved blood compared to fresh blood
(Verschoor et al., 2017). A rest period after
thawing does not rescue the NK cell enumera-
tion in cryopreserved PBMCs (Lemieux et al.,
2017). In contrast, another study that included
no rest period after thawing found that NK cell
enumeration was not affected by cryopreser-
vation of PBMCs compared to fresh blood
(Draxler et al., 2017). The reasons for the dis-
crepancy between these studies are unclear.
Monocytes
Two studies showed that monocyte counts
were more elevated in cryopreserved blood
or cryopreserved PBMCs compared to fresh
blood (Draxler et al., 2017; Verschoor et al.,
2017). However, neither one of these stud-
ies allowed the cells to rest prior to staining.
The proportion of monocytes in cryopreserved
PBMCs was similar to fresh blood after both 1
and 24 hr of rest after thawing (Lemieux et al.,
2017).
Dendritic cells
Dendritic cells are some of the least rep-
resented cells in PBMCs and are sensitive to
freeze/thaw cycles. Makino and Baba (1997)
showed that upon proper cryopreservation
conditions (25% FBS and 10% DMSO), den-
dritic cells could be frozen and properly
thawed and cultured in the same manner as for
freshly isolated PBMCs. But while the den-
dritic cells retain their function after cryop-
reservation, they appear to increase in numbers
(Draxler et al., 2017; Verschoor et al., 2017).
Dendritic cell subsets are affected by PBMC
manipulation. A study showed that Ficoll sep-
aration, regardless of cryopreservation status,
increases the ratio of plasmacytoid dendritic to
myeloid dendritic cells (Gerrits et al., 2007).




Standardization of cryopreservation and
thawing procedures
To obtain reproducible results during im-
munophenotyping, it is important to minimize
pre-analytical variability by standardizing cry-
opreservation and thawing of PBMCs. These
include the following.
1. The time between blood collection and
sample processing should remain consistently
within 48 hr as viability of cells after cryop-
reservation is dramatically reduced if the de-
lay between sample collection and processing
is >48 hr (data not shown).
2. Although CPTTM tubes are shipped in
styrofoam containers with room temperature
gel packs, it is critical to keep the tubes up-
right at room temperature for 30 min prior to
processing so that the gel layer can equilibrate
to room temperature.
3. Rate of cooling during sample freezing
is an important step. The cooling rate must be
maintained at its optimum rate as cell survival
will decrease if more or less of the optimal
cooling rate is used (Hubel & Skubitz, 2017).
The PBMC cryovials were stored in a styro-
foam container at –80°C to control the cooling
rate. One can also use a freezer specifically
designed to cryopreserve cells or a Mr. Frosty
(Nalgene), which is a container using the cool-
ing property of isopropanol to maintain an op-
timum cooling rate of 1°C/min.
4. Using cold solutions during the cryop-
reservation process has been shown to improve
viability and functional recovery of PBMCs
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comparing the use of cold freezing medium
versus room temperature freezing medium,
Tree (2004) noted that PBMCs frozen us-
ing cold medium performed more similarly
to fresh blood in a functional assay (e.g., T
cell response to tetanus). Cold 20% DMSO
(in 1× RPMI) solution and cold 20% FBS (in
1× RPMI) were used to process the PBMCs.
5. Storage temperature, and more specif-
ically changes in storage temperature, can
affect cell viability and subsets recovery
(Cosentino et al., 2003). Storing the control
PBMCs and study samples in the same liquid
nitrogen freezer allows evaluation of any dif-
ferences in subset recovery or viability due to
changes in storage temperature.
6. Fast thawing at 37°C is an important step
to standardize across technicians. A thawing
time of 60 sec to maintain consistency between
technicians is recommended.
7. Based on previously published data
(Lemieux et al., 2017), cells were rested 1 hr
at 37°C after thawing to restore most immune
cell subsets to their level in fresh blood. The
cell subsets of interest are the major determi-
nant of whether to include a rest period and to
decide on the duration of the rest period.
8. Appropriate training of technicians is
key to standardization. While CPTTM vacu-
tainers are easier to use than a Ficoll gradient,
cryopreserving PBMCs still requires a certain
level of technical skill. The technicians pro-
cessing the samples for cryopreservation were
trained by a senior member of the staff on all
aspects of the procedure (cell count, cooling
of samples, recording of reagent lot numbers,
etc.). A senior staff member then observed
trainees closely before being allowed to work
on study samples. A similar training method
was used in the flow laboratory. To moni-
tor proper thawing technique, HRS controls




Variability in immunophenotyping assays
can be minimized using the following proce-
dures.
1. Standardize flow cytometer configura-
tions across multiple instruments. For exam-
ple, both flow cytometers used for HRS were
equipped with similar lasers (blue, UV, red,
and violet) and the same filters for each PMT.
2. Establish a daily thorough flow cytome-
ter quality control protocol as described in Ba-
sic Protocol 3. Minimize downtime by care-
fully monitoring CST and URB to catch laser
drift prior to outright quality control failure.
Use frozen PBMCs from a healthy volun-
teer to perform daily compensation setup and
calculations.
3. During the experimental setup, perform
all steps required to check the antibodies used
in the study. This includes testing all antibodies
in a dilution series and including all the FMO
(fluorescence minus one) controls. If possi-
ble, purchase antibodies in bulk so that they
are from the same lot. However, if that is not
possible, test every new lot of reagents using
control samples and ensure similar values for
all subsets before using new lots of reagents on
study samples. Use PBMC controls to check
the consistency of panels over the course of
the study.
4. In the context of immunophenotyping,
use controls to check both reagents (antibod-
ies and buffers) as well as technical abilities
and consistency during the study. Train new
technicians during the study. The PBMC con-
trols proved to be an invaluable tool to test the
readiness of each new technician. As described
in Basic Protocol 3, have each new trainee im-
munophenotype each control three times on
different days. If all measured immune popu-
lations were within the established range, the
new trainee should start running HRS samples.
If immune populations were out of range, ad-
ditional training should be provided.
5. When running samples for HRS, group
ten samples per batch for processing from
thawing to immunophenotyping. Once all
technicians become proficient, slowly increase
the number of samples per batch (up to 16);
however, an increase in the number of samples
with low cell count (data not shown) has been
observed. This increase in number of samples
per batch only affected total thawing time. It
is suspected that the increased time at 37°C
before centrifuging and removing DMSO af-
fected cell viability.
6. During initial panel testing, identify
lower numbers of dendritic cells if the samples
are kept on ice water rather than “regular ice.”
Process samples daily in five scaled batches
of ten samples each to minimize sample time
on ice (generally 2 hr maximum per batch),
which minimized variability in dendritic cell
measurement.
7. The fluidics in the flow cytometer must
be cleaned daily and a full clean of the fluidics
should be performed monthly.
Anticipated Results
Using the cryopreservation procedures de-
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able to process up to 80 samples daily and
all samples were processed on the same day
samples were received at the laboratory. Im-
munophenotyping of up to 50 samples daily
following the abovementioned protocols was
also achieved. The total failure rate was 5%
when using the quality control procedures out-
lined in this unit.
Time Considerations
Cryopreservation
Cryopreservation of PBMCs is time con-
suming and requires an experienced techni-
cian. CPTTM vacutainers were chosen to save
time over a Ficoll separation. It has been shown
that viability and T cell subset enumeration
is similar in cryopreserved PBMCs that have
been isolated using either a CPTTM vacutainer
or the Ficoll separation method (Ruitenberg,
Mulder, Maino, Landay, & Ghanekar, 2006).
The protocol for cryopreservation of PBMCs
(see Basic Protocol 1) is straightforward and
can be done in 3 hr for one CPTTM tube.
Since the central laboratory received more than
one sample a day, the separation and cryop-
reservation of PBMCs were batched. This only
marginally increased processing time to 4 hr
per batch. If several trained technicians are
assigned to cryopreservation and processing
was staggered, upwards of 80 samples could
be cryopreserved in 1 day without the need for
automation.
Flow cytometry set up
To limit sample loss due to instrument fail-
ure, no samples are thawed until both (or at
least one) flow cytometers have passed qual-
ity control procedures, which takes 40 min.
The lasers need to warm up for a minimum of
20 min prior to use. This allows enough time to
refill both sheath tanks, empty waste tank, and
prime the fluidic systems of the flows. After
the CST has been run, set up the URB exper-
iment and its associated application settings.
The cryopreserved PBMCs used for compen-
sation setup are also thawed during this time.
PBMC preparation from thawing to
immunophenotyping
The study samples were processed in
batches of ten samples from thawing to stain-
ing. During an 8-hr workday, two technicians
can prepare five sets of ten samples without re-
quiring the need for any automation and with-
out compromising data quality. Immunophe-
notyping of PBMCs from removal of cryovials
from liquid nitrogen to staining took 2 hr
with 35 to 40 min of hands-on work at the
bench. By staggering the batches appropri-
ately, minimal time has been achieved where
the samples sit on ice and all 50 samples were
processed during an 8-hr workday.
Summary
Previous studies indicate that cryopreserv-
ing whole blood or isolated PBMCs both yield
similar results for immunophenotyping and
functional studies. The effect of cryopreserva-
tion on various cell subsets has been described
previously and use of a rest period after thaw-
ing can help restore immune cell distributions
to those seen in fresh blood. Standardization of
cryopreservation, thawing and immunopheno-
typing procedures and use of control samples,
stored and analyzed in a manner identical to
study samples, can significantly reduce vari-
ability of immunophenotyping measurements
in large scale population studies.
Acknowledgements
This work was funded by a grant from the
National Institute of Aging (U01 AG009740).
The authors would like to thank Sharon
Minnerath, Vicky Makky, and Eileen Studt
for assistance with cryopreservation and
Zach Flaten, Devon Hunter-Schlichting, Erin
Cassidy, Paige Hartman, Tori Contreras,
and Ramya Ramasubramian for assistance
with immunophenotyping of cryopreserved
samples.
Conflict of Interest
The authors have no conflict of interest to
report.
Literature Cited
Cheng, L., Wang, L. E., Spitz, M. R., &
Wei, Q. (2001). Cryopreserving whole blood
for functional assays using viable lympho-
cytes in molecular epidemiology studies. Can-
cer Letters, 166(2), 155–163. doi: 10.1016/
S0304-3835(01)00400-1.
Cosentino, L. M., Corwin, W., Baust, J. M., Diaz-
Mayoral, N., Cooley, H., Shao, W., Van Buskirk,
R., & Baust, J. G. (2007). Preliminary report:
Evaluation of storage conditions and cryocock-
tails during peripheral blood mononuclear cell
cryopreservation. Cell Preservation Technology,
5(4). doi: 10.1089/cpt.2007.9987.
Costantini, A., Mancini, S., Giuliodoro, S., Butini,
L., Regnery, C. M., Silvestri, G., & Montroni, M.
(2003). Effects of cryopreservation on lympho-
cyte immunophenotype and function. Journal
of Immunological Methods, 278(1-2), 145–155.
doi: 10.1016/S0022-1759(03)00202-3.
Draxler, D. F., Madondo, M. T., Hanafi, G., Pleban-
ski, M., & Medcalf, R. L. (2017). A flow cyto-
metric analysis to efficiently quantify multiple






Supplement 84 Current Protocols in Cytometry
blood. Cytometry Part A, 91(4), 336–350. doi:
10.1002/cyto.a.23080.
Elkord, E. (2009). Frequency of human T regu-
latory cells in peripheral blood is significantly
reduced by cryopreservation. Journal of Im-
munological Methods, 347(1-2), 87–90. doi:
10.1016/j.jim.2009.06.001.
Elliott, P., Peakman, T. C., & UK Biobank (2008).
The UK Biobank sample handling and stor-
age protocol for the collection, processing and
archiving of human blood and urine. Interna-
tional Journal of Epidemiology, 37(2), 234–244.
doi: 10.1093/ije/dym276.
Friedman, G. D., Cutter, G. R., Donahue, R.
P., Hughes, G. H., Hulley, S. B., Jacobs, D.
R. Jr, . . . Savage, P. J. (1988). CARDIA:
Study design, recruitment, and some charac-
teristics of the examined subjects. Journal of
Clinical Epidemiology, 41(11), 1105–1116. doi:
10.1016/0895-4356(88)90080-7.
Gerrits, J. H., Athanassopoulos, P., Vaessen, L. M.,
Klepper, M., Weimar, W., & van Besouw, N. M.
(2007). Peripheral blood manipulation signifi-
cantly affects the result of dendritic cell moni-
toring. Transplant Immunology, 17(3), 169–177.
doi: 10.1016/j.trim.2006.11.006.
Hubel, A. & Skubitz, A. P. N. (2017) Principles
of Cryopreservation. In Biobanking of Human
Biospecimens. (P. Hainaut, J. Vaught, K. Zat-
loukal, & M. Pasterk, eds.), Springer, Cham,
Switzerland.
Hughes, G. H., Cutter, G., Donahue, R., Fried-
man, G. D., Hulley, S., Hunkeler, E., Jacobs,
D. R. Jr et al. (1987). Recruitment in the coro-
nary artery disease risk development in young
adults (Cardia) study. Controlled Clinical Tri-
als, 8(4), 68S–73S. doi: 10.1016/0197-2456(87)
90008-0.
Kalina, T., Flores-Montero, J., van der Velden, V.
H. J., Martin-Ayuso, M., Böttcher, S., Ritgen,
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